Valeant's annual report is finally out

After months of delays, a Senate hearing, and a percipitous stock fall, Valeant Pharmaceuticals finally filed their annual 10-k report to the SEC Friday morning.

The document has been delayed multiple times as the comapny reviewed financial documents related to a speacialty pharmacy, Philaor, associated with the company.

The company originally delayed the filing on March 21, stating they had created an ad hoc committee to review Valeant’s financial statements.

The committe then annouced they had completed their review on April 5.

More to come…

NOW WATCH: FORMER GREEK FINANCE MINISTER: The single largest threat to the global economy

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.